(2Z)-2-(9-ethoxy-8-methoxy-2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-ylidene)-5-piperidin-1-ylpentanenitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (2Z)-2-(9-ethoxy-8-methoxy-2,3,4,4a,5,10b-hexahydro-1H-phenanthridin-6-ylidene)-5-piperidin-1-ylpentanenitrile
• 化学式: C₂₆H₃₇N₃O₂
• 分子量: 423.6
• InChiKey: NPQGISOKUJURKT-XHPQRKPJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  57.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] ISOQUINOLINE DERIVATIVES<br/>[FR] DERIVES D'ISOQUINOLINE
  申请人：SANOFI SYNTHELABO

  公开号：WO2001064648A1

  公开（公告）日：2001-09-07

  New compounds of the general formula (I) are strong and selective inhibitors of PDE4 enzyme and they are presumably suitable for the treatment of for instance asthma, chronic obstructive pulmonary disease (COPD) and rheumatoid arthritis.
• [EN] COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION<br/>[FR] COMBINAISONS D'INHIBITEURS DE PDE-V ET D'ANTAGONISTES DE NK1 DANS LE TRAITEMENT DE LA DEPRESSION
  申请人：PFIZER PROD INC

  公开号：WO2003105815A1

  公开（公告）日：2003-12-24

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with a PDE IV inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and a PDE IV inhibitor.
• [EN] TREATMENT FOR DEPRESSION AND ANXIETY BY THE COMBINATION OF A PDE IV INHIBITOR AND AN ANTIDEPRESSANT OR AN ANXIOLYTIC AGENT<br/>[FR] TRAITEMENT DE LA DEPRESSION ET DE L'ANXIETE PAR LA COMBINAISON D'UN INHIBITEUR DE PDE IV ET D'UN ANTIDEPRESSEUR OU AGENT ANXIOLYTIQUE
  申请人：PFIZER PROD INC

  公开号：WO2003105902A1

  公开（公告）日：2003-12-24

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a PDE IV inhibitor in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a PDE IV inhibitor and an anxiolytic agent or antidepressant.